Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has made significant strides in its pipeline across key therapeutic areas in the first half of 2024. The company reached major milestones in cardiovascular, renal, metabolic health (CRM), and oncology, with further data read-outs expected in oncology, mental health, and pulmonary fibrosis later in the year.
Hubertus von Baumbach, Chairman of the Board of Managing Directors, highlighted the company's increased investments in R&D and the acceleration of launch preparedness for late-stage assets. Boehringer Ingelheim advanced its pipeline with five new phase I, II, or III initiations in cardiometabolic diseases, mental health, and oncology, and secured two additional fast track designations for programs in inflammation. The company also announced nine R&D partnership agreements, enhancing its human pharma portfolio.
Net sales for the first six months of 2024 rose by 7.4% year-on-year to EUR 12.9 billion, driven by high patient demand for Boehringer’s medications, including the JARDIANCE® product family and OFEV® in Human Pharma, and NEXGARD® in Animal Health.
In Human Pharma, Boehringer Ingelheim achieved positive Phase II data for survodutide in metabolic dysfunction-associated steatohepatitis (MASH), showing significant improvements in liver disease due to MASH. The company also initiated a Phase III trial in chronic heart failure for its novel selective aldosterone synthase inhibitor (ASi) in combination with empagliflozin and joined a multi-year sponsorship of the American Heart Association's Cardiovascular-Kidney-Metabolic Health Initiative.
In oncology, Boehringer Ingelheim is re-entering with targeted investments, with the Phase Ia/Ib trial of Zongertinib showing promising efficacy in patients with HER2 aberration-positive solid tumors. The company's Human Pharma business grew by 9.3% year on year, with net sales standing at EUR 10.3 billion.
In Animal Health, the VAXXITEK® portfolio of poultry vaccines expanded, and the company launched BULTAVO 3™, a new vaccine against bluetongue virus serotype 3 (BTV-3). Despite slower growth in the Animal Health business, sales of the NEXGARD® parasiticides brands grew by 15.9%.
Looking ahead, Boehringer Ingelheim aims for up to 25 new treatment launches in Human Pharma until 2030 and 20 additional launches in Animal Health until 2026, including product updates, indication expansion, and new products.
